Experimental cancer drug reduces SIV levels in the brain, targeting immune cells harboring HIV.

Experimental cancer drug shows promise in clearing HIV from brain: Tulane study. A cancer drug significantly reduced SIV (nonhuman primate HIV equivalent) levels in the brain by targeting & depleting immune cells harboring the virus. Published in Brain journal, this discovery marks a crucial step towards eliminating HIV from hard-to-reach reservoirs & tackling brain-related issues caused by HIV, even in those on effective treatment.